spironolactone has been researched along with Muscle Contraction in 17 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Muscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the effects of spironolactone, an unselective mineralocorticoid-receptor antagonist, on in vivo cardiac haemodynamics, cardiomyocyte damage and fibrosis in prednisolone treated Sgcd-null mice." | 3.76 | Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Lochmüller, H; MacGowan, GA; Straub, V, 2010) |
| "Pre-treatment with aldosterone also significantly extended the mean (SEM) time required to reach 50% relaxation of a noradrenaline-induced contraction, of 9." | 1.35 | Effect of aldosterone on isolated human penile corpus cavernosum tissue. ( Anzai, H; Kagawa, J; Kanayama, HO; Kawanishi, Y; Kishimoto, T; Kojima, K; Muguruma, H; Numata, A; Sugiyama, H; Tanimoto, S; Yamanaka, M, 2008) |
| " We guess that SP can be used in well regulated dosed with least side effects to arrest preterm labor on human being in the future." | 1.29 | The effect of spironolactone on the rat uterus. ( Coksevim, B; Tayyar, M, 1994) |
| "Indapamide has a prolonged saluretic action which in combination with the direct vascular effects may well account for its antihypertensive activity." | 1.25 | Antihypertensive action of indapamide. Comparative studies in several experimental models. ( Kyncl, J; Oheim, K; Seki, T; Solles, A, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (52.94) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janssen, PM | 1 |
| Murray, JD | 1 |
| Schill, KE | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Rafael-Fortney, JA | 1 |
| Bauer, R | 1 |
| Blain, A | 1 |
| Greally, E | 1 |
| Lochmüller, H | 1 |
| Bushby, K | 1 |
| MacGowan, GA | 1 |
| Straub, V | 1 |
| Gros, R | 1 |
| Ding, Q | 1 |
| Davis, M | 1 |
| Shaikh, R | 1 |
| Liu, B | 1 |
| Chorazyczewski, J | 1 |
| Pickering, JG | 1 |
| Feldman, RD | 1 |
| Myers, B | 1 |
| Greenwood-Van Meerveld, B | 1 |
| Muguruma, H | 1 |
| Kawanishi, Y | 1 |
| Sugiyama, H | 1 |
| Kagawa, J | 1 |
| Tanimoto, S | 1 |
| Yamanaka, M | 1 |
| Kojima, K | 1 |
| Anzai, H | 1 |
| Numata, A | 1 |
| Kishimoto, T | 1 |
| Kanayama, HO | 1 |
| Waldorff, S | 1 |
| Hansen, PB | 1 |
| Egeblad, H | 1 |
| Berning, J | 1 |
| Buch, J | 1 |
| Kjaergård, H | 1 |
| Steiness, E | 1 |
| Ataullakhanova, DM | 1 |
| Coksevim, B | 2 |
| Tayyar, M | 2 |
| Sorrentino, R | 1 |
| Autore, G | 1 |
| Cirino, G | 1 |
| d'Emmanuele de Villa Bianca, R | 1 |
| Calignano, A | 1 |
| Vanasia, M | 1 |
| Alfieri, C | 1 |
| Sorrentino, L | 1 |
| Pinto, A | 1 |
| Frenkl, R | 1 |
| Szeberényi, S | 1 |
| Kyncl, J | 1 |
| Oheim, K | 1 |
| Seki, T | 1 |
| Solles, A | 1 |
| Mikami, H | 1 |
| Ogihara, T | 1 |
| Ohde, H | 1 |
| Katahira, K | 1 |
| Kohara, K | 1 |
| Kumahara, Y | 1 |
| Dacquet, C | 1 |
| Loirand, G | 1 |
| Mironneau, C | 1 |
| Mironneau, J | 1 |
| Pacaud, P | 1 |
| Strauer, BE | 2 |
| Avenhaus, H | 1 |
| Nose, M | 1 |
| Schröder, R | 1 |
| Schüren, KP | 1 |
| Biamino, G | 1 |
| Dennert, J | 1 |
| Meyer, V | 1 |
| Sadée, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
1 review available for spironolactone and Muscle Contraction
| Article | Year |
|---|---|
[Effect of diuretics on the cardiovascular system].
Topics: Animals; Biological Transport; Blood Pressure; Cardiovascular System; Diuretics; Enzyme Activation; | 1980 |
16 other studies available for spironolactone and Muscle Contraction
| Article | Year |
|---|---|
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Diuretics; Dystrophin; Female; Gene Expression; | 2014 |
Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism.
Topics: Administration, Oral; Animals; Body Weight; Fibrosis; Glucocorticoids; Heart; Heart Diseases; Hemody | 2010 |
Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol.
Topics: Aldosterone; Animals; Cells, Cultured; Eplerenone; Estradiol; Estrogen Receptor alpha; Muscle Contra | 2011 |
Corticosteroid receptor-mediated mechanisms in the amygdala regulate anxiety and colonic sensitivity.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Catheterization; Colon; Drug Implants; Hormone Antagon | 2007 |
Effect of aldosterone on isolated human penile corpus cavernosum tissue.
Topics: Adult; Aged; Aldosterone; Humans; In Vitro Techniques; Male; Middle Aged; Mineralocorticoid Receptor | 2008 |
Interactions between digoxin and potassium-sparing diuretics.
Topics: Adult; Digoxin; Drug Interactions; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney; | 1983 |
The effect of spironolactone of the rat uterus.
Topics: Acetylcholine; Animals; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Muscle Contra | 1993 |
The effect of spironolactone on the rat uterus.
Topics: Animals; Diethylstilbestrol; Dose-Response Relationship, Drug; Female; Ileum; In Vitro Techniques; I | 1994 |
Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings.
Topics: Animals; Aorta, Thoracic; Calcium Channel Blockers; Canrenoic Acid; Canrenone; In Vitro Techniques; | 2000 |
Enzyme inducing effect of muscular exertion in the rat.
Topics: Animals; Canrenone; Dihydrotestosterone; Dose-Response Relationship, Drug; Enzyme Induction; Hexobar | 1976 |
Antihypertensive action of indapamide. Comparative studies in several experimental models.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Chlorthalidone; Diuretics; Dogs; | 1975 |
Direct vascular effects of 19-hydroxyandrostenedione.
Topics: Aldosterone; Androstenedione; Animals; Desipramine; Dose-Response Relationship, Drug; Ear; Female; H | 1989 |
Spironolactone inhibition of contraction and calcium channels in rat portal vein.
Topics: Animals; Calcium; Calcium Channel Blockers; In Vitro Techniques; Membrane Potentials; Muscle Contrac | 1987 |
The influence of the aldosterone-antagonist spironolactone on myocardial contractility.
Topics: Animals; Cardiac Output; Cats; Dose-Response Relationship, Drug; Heart; Muscle Contraction; Muscle T | 1973 |
Evidence for a positive inotropic effect of aldadiene (-K, -Na) on the isolated ventricular myocardium.
Topics: Animals; Cats; Electric Stimulation; Extracellular Space; In Vitro Techniques; Muscle Contraction; M | 1972 |
[Effect of aldactone on the dynamics and contractility of the heart].
Topics: Cardiac Catheterization; Digoxin; Heart; Hemodynamics; Humans; Mineralocorticoid Receptor Antagonist | 1971 |